T-NeuroDx today announced significant progress across its diagnostic platform, including advancements in clinical research, strategic partnerships, and fundraising efforts to support its next phase of growth.
The company has sharpened its scientific and commercial strategy, aligning product development, validation, and go-to-market planning to accelerate its path toward clinical adoption and commercialization.
Financing to Accelerate Development
T-NeuroDx has entered diligence with a potential lead investor to support a $2 million financing round. Proceeds are expected to further de-risk the platform and position the company for a projected $8 million Series A raise in the coming year.
Key initiatives supported by this financing include:
- Continued assay optimization and biomarker validation to support peer-reviewed publication and scientific adoption
- Launch of a Research Use Only (RUO) kit and Lab Developed Tests (LDTs) with clinical laboratory partners
- Advancement of regulatory and reimbursement strategies, including FDA pre-submission and application for Breakthrough Device designation
Advancing Clinical Research and Scientific Leadership
The company is actively generating clinical data through a $500,000 NIH-funded study in collaboration with the University of Southern California, with initial results anticipated by the end of the first quarter and funding secured through mid-2026. Additional grant applications are in development with leading academic and industry collaborators.
T-NeuroDx’s platform continues to gain recognition within the scientific community, with recent and upcoming presentations at major conferences, including:
- Society for Neuroscience (SfN)
- Clinical Trials on Alzheimer’s Disease (CTAD)
- AD/PD™ 2026 Alzheimer’s & Parkinson’s Diseases Conference
These presentations underscore the potential of the company’s proprietary hiT Cells™ technology as a differentiated prognostic biomarker that complements existing amyloid-tau-neurodegeneration (ATN) diagnostic frameworks.
Expanding Strategic Partnerships
T-NeuroDx is actively engaging with clinical laboratories, diagnostics leaders, and technology partners to advance assay validation and future integration opportunities. Ongoing discussions include TrilliumBiO, Beckman Coulter, Immudex, BD, and LabCorp.